Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients (Q36817119)

16 August 2017

1 reference

title

Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients (English)

1 reference

16 August 2017

1 reference

1 reference

3

Darell D Bigner

1 reference

16 August 2017

1

David A Reardon

1 reference

16 August 2017

Michael R Zalutsky

2

1 reference

16 August 2017

1 May 2007

1 reference

16 August 2017

13

1 reference

Expert Review of Anticancer Therapy

inferred from page(s)

published in

1 reference

16 August 2017

7

1 reference

16 August 2017

5

1 reference

16 August 2017

675-687

1 reference

Genetic pathways to glioblastoma: a population-based study

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Effects of treatment on long-term survivors with malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

External beam radiotherapy: hard facts and painful realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Mechanisms of disease: the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Assumptions in the radiotherapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Therapeutic antibodies--delivering the promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Monoclonal antibodies M340 and UJ181.4 recognize antigens associated with primitive neuroectodermal tumours/tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

MRP3, an organic anion transporter able to transport anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Analysis of structure and function of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Tenascin expression in human glioma cell lines and normal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Clinical impact and functional aspects of tenascin-C expression during glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Improved tumor targeting by combined use of two antitenascin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

A six-armed oligomer isolated from cell surface fibronectin preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.675

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.675

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vxz7wtsbcvb5dhzsvvhdwszyh4

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_vxz7wtsbcvb5dhzsvvhdwszyh4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vxz7wtsbcvb5dhzsvvhdwszyh4

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/vxz7wtsbcvb5dhzsvvhdwszyh4

30 July 2022